Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies

Andrew M. Chiu; Rohan Savoor; Andrew C. Gordon; Ahsun Riaz; Kent T. Sato; Elias Hohlastos; Riad Salem; Robert J. Lewandowski

doi:10.1016/j.jvir.2022.12.021

Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies

Andrew M. Chiu, Rohan Savoor, Andrew C. Gordon, Ahsun Riaz, Kent T. Sato, Elias Hohlastos, Riad Salem, Robert J. Lewandowski^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Purpose: To evaluate the safety and efficacy of yttrium-90 (⁹⁰Y) radiation segmentectomy (RS) in the treatment of oligometastatic secondary hepatic malignancies. Materials and Methods: This institutional review board–approved retrospective study evaluated 16 patients with oligometastatic secondary hepatic malignancies who were treated with RS. The median patient age was 61.9 years (range, 38.6–85.7 years). Of the 16 patients, 11 (68.8%) presented with solitary lesions. The median index tumor size was 3.1 cm (95% CI, 2.3–3.9). Primary outcomes were evaluation of clinical and biochemical toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, and imaging response using Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary outcomes were time to progression (TTP) and overall survival (OS) as estimated by the Kaplan-Meier method. Results: Clinical Grade 3 toxicities were limited to 1 (6.7%) patient who experienced fatigue, abdominal pain, nausea, and vomiting. Biochemical Grade 3 toxicities occurred in 1 (6.7%) patient who experienced lymphopenia. No Grade 4 clinical or biochemical toxicities were identified. Disease control was achieved in 14 (93.3%) of 15 patients. The median TTP of the treated tumor was 72.9 months (95% CI, 11.2 to no estimate). The median OS was 60.9 months (95% CI, 24.7 to no estimate). Conclusions: ⁹⁰Y RS displayed an excellent safety profile and was effective in achieving a high disease control rate in the treatment of oligometastatic secondary hepatic malignancies.

Original language	English (US)
Pages (from-to)	362-368
Number of pages	7
Journal	Journal of Vascular and Interventional Radiology
Volume	34
Issue number	3
DOIs	https://doi.org/10.1016/j.jvir.2022.12.021
State	Published - Mar 2023

Funding

A.C.G. is a paid consultant for ABK Medical. A.R. receives honorary payments from and is a consultant for Boston Scientific. K.T.S. is a paid consultant for Varian Medical Systems. R.Sal. is a paid consultant for Boston Scientific, Sirtex, Cook, Bard, Eisai, Genetech, and AstraZeneca. R.J.L. reports institutional grants from the National Institutes of Health (R01CA233878); receives consulting fees from Boston Scientific, BD, Varian, ABK Medical, Alhambra Medical, and AstraZeneca; reports honorary payments from Boston Scientific; and has a leadership role in the Executive Council of the Society of Interventional Radiology. None of the other authors have identified a conflict of interest.

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jvir.2022.12.021

Cite this

@article{c54b8f638a9a47f195ca6ae0728d4b10,

title = "Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies",

abstract = "Purpose: To evaluate the safety and efficacy of yttrium-90 (90Y) radiation segmentectomy (RS) in the treatment of oligometastatic secondary hepatic malignancies. Materials and Methods: This institutional review board–approved retrospective study evaluated 16 patients with oligometastatic secondary hepatic malignancies who were treated with RS. The median patient age was 61.9 years (range, 38.6–85.7 years). Of the 16 patients, 11 (68.8%) presented with solitary lesions. The median index tumor size was 3.1 cm (95% CI, 2.3–3.9). Primary outcomes were evaluation of clinical and biochemical toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, and imaging response using Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary outcomes were time to progression (TTP) and overall survival (OS) as estimated by the Kaplan-Meier method. Results: Clinical Grade 3 toxicities were limited to 1 (6.7%) patient who experienced fatigue, abdominal pain, nausea, and vomiting. Biochemical Grade 3 toxicities occurred in 1 (6.7%) patient who experienced lymphopenia. No Grade 4 clinical or biochemical toxicities were identified. Disease control was achieved in 14 (93.3%) of 15 patients. The median TTP of the treated tumor was 72.9 months (95% CI, 11.2 to no estimate). The median OS was 60.9 months (95% CI, 24.7 to no estimate). Conclusions: 90Y RS displayed an excellent safety profile and was effective in achieving a high disease control rate in the treatment of oligometastatic secondary hepatic malignancies.",

author = "Chiu, {Andrew M.} and Rohan Savoor and Gordon, {Andrew C.} and Ahsun Riaz and Sato, {Kent T.} and Elias Hohlastos and Riad Salem and Lewandowski, {Robert J.}",

note = "Publisher Copyright: {\textcopyright} 2022 SIR",

year = "2023",

month = mar,

doi = "10.1016/j.jvir.2022.12.021",

language = "English (US)",

volume = "34",

pages = "362--368",

journal = "Journal of Vascular and Interventional Radiology",

issn = "1051-0443",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies

AU - Chiu, Andrew M.

AU - Savoor, Rohan

AU - Gordon, Andrew C.

AU - Riaz, Ahsun

AU - Sato, Kent T.

AU - Hohlastos, Elias

AU - Salem, Riad

AU - Lewandowski, Robert J.

PY - 2023/3

Y1 - 2023/3

N2 - Purpose: To evaluate the safety and efficacy of yttrium-90 (90Y) radiation segmentectomy (RS) in the treatment of oligometastatic secondary hepatic malignancies. Materials and Methods: This institutional review board–approved retrospective study evaluated 16 patients with oligometastatic secondary hepatic malignancies who were treated with RS. The median patient age was 61.9 years (range, 38.6–85.7 years). Of the 16 patients, 11 (68.8%) presented with solitary lesions. The median index tumor size was 3.1 cm (95% CI, 2.3–3.9). Primary outcomes were evaluation of clinical and biochemical toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, and imaging response using Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary outcomes were time to progression (TTP) and overall survival (OS) as estimated by the Kaplan-Meier method. Results: Clinical Grade 3 toxicities were limited to 1 (6.7%) patient who experienced fatigue, abdominal pain, nausea, and vomiting. Biochemical Grade 3 toxicities occurred in 1 (6.7%) patient who experienced lymphopenia. No Grade 4 clinical or biochemical toxicities were identified. Disease control was achieved in 14 (93.3%) of 15 patients. The median TTP of the treated tumor was 72.9 months (95% CI, 11.2 to no estimate). The median OS was 60.9 months (95% CI, 24.7 to no estimate). Conclusions: 90Y RS displayed an excellent safety profile and was effective in achieving a high disease control rate in the treatment of oligometastatic secondary hepatic malignancies.

AB - Purpose: To evaluate the safety and efficacy of yttrium-90 (90Y) radiation segmentectomy (RS) in the treatment of oligometastatic secondary hepatic malignancies. Materials and Methods: This institutional review board–approved retrospective study evaluated 16 patients with oligometastatic secondary hepatic malignancies who were treated with RS. The median patient age was 61.9 years (range, 38.6–85.7 years). Of the 16 patients, 11 (68.8%) presented with solitary lesions. The median index tumor size was 3.1 cm (95% CI, 2.3–3.9). Primary outcomes were evaluation of clinical and biochemical toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, and imaging response using Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary outcomes were time to progression (TTP) and overall survival (OS) as estimated by the Kaplan-Meier method. Results: Clinical Grade 3 toxicities were limited to 1 (6.7%) patient who experienced fatigue, abdominal pain, nausea, and vomiting. Biochemical Grade 3 toxicities occurred in 1 (6.7%) patient who experienced lymphopenia. No Grade 4 clinical or biochemical toxicities were identified. Disease control was achieved in 14 (93.3%) of 15 patients. The median TTP of the treated tumor was 72.9 months (95% CI, 11.2 to no estimate). The median OS was 60.9 months (95% CI, 24.7 to no estimate). Conclusions: 90Y RS displayed an excellent safety profile and was effective in achieving a high disease control rate in the treatment of oligometastatic secondary hepatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85146001288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146001288&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2022.12.021

DO - 10.1016/j.jvir.2022.12.021

M3 - Article

C2 - 36526074

AN - SCOPUS:85146001288

SN - 1051-0443

VL - 34

SP - 362

EP - 368

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

IS - 3

ER -

Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this